FDA supports new medication for therapy of adults with chronic kidney infection Kumar Jeetendra | May 1, 2021 Today, the U.S. Food and Drug Administration accepted Farxiga (dapagliflozin) oral tablets to decrease the risk of kidney function decline, kidney failure, cardiovascular death and hospitalization for heart failure in adults with chronic kidney disease who are at risk of disease progression. Chronic kidney disease occurs when the kidneys are damaged and can’t filter blood …
Immunotherapy treatments for nephrological autoimmune illnesses may help treat serious Coronavirus Kumar Jeetendra | June 8, 2021 Various viruses and bacteria have been known to cause autoimmune diseases where there’s such a predisposition. This phenomenon also seems to play a major part SARS-CoV-2, especially in severe courses. The body’s own immune cells are activated, with the formation of autoantibodies that attack the body’s own healthy cell structures (proteins, autoantigens); deposits of immune …